You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on prostate cancer.
Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
The framework is meant to guide healthcare providers in facilitating prostate cancer genetic testing in a timely and responsible way, the researchers said.
The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.
Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.
The approval is based on results of the PROfound trial, which included men with mutations in BRCA1/2 or ATM, and 12 other genes associated with the HRR pathway.
The accelerated approval was based on data from the TRITON2 trial involving metastatic patients with BRCA mutations and homologous recombination deficiency.
Data presented at ACMG's online annual meeting suggests that more than 10 percent of prostate cancer patients across disease stages carry inherited cancer-related variants.
Merck and AstraZeneca's PARP inhibitor was reported previously to stave off disease progression, based on which supplemental new drug application was filed with the FDA.
Researchers reported that when CDK12-mutated patients were treated with PD-1 inhibitors in fourth- or later-line settings, a third of them responded.